Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (RGEN) drives innovation in bioprocessing technologies critical for biologics manufacturing, serving pharmaceutical companies and CDMOs worldwide. This page provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access comprehensive coverage of Repligen's strategic initiatives, including financial results, product innovations, and partnership announcements. Our curated news collection enables stakeholders to track the company's impact on biomanufacturing efficiency and therapeutic development pipelines.
Explore updates across key operational areas: quarterly earnings disclosures, regulatory milestones for filtration systems and chromatography products, R&D advancements in process analytics, and global expansion efforts. Content is rigorously verified to ensure alignment with market-moving developments.
Bookmark this page for streamlined access to Repligen's evolving market position. Regularly updated coverage supports informed analysis of the company's role in advancing next-generation drug manufacturing technologies.
Repligen (NASDAQ:RGEN) has announced that it will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The company will issue a press release before the market opens and host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six-month periods ended June 30, 2024.
Investors can access the conference call by dialing (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. A webcast will also be available via the Investor Relations section of Repligen's website. Both the call and webcast will be archived for future access, with replay dial-in numbers provided for U.S., Canadian, and international callers.
Repligen (NASDAQ:RGEN) announced a leadership transition plan where Tony J. Hunt will move from CEO to Executive Chair, and Olivier Loeillot will become President and CEO, effective September 1, 2024. Hunt has been CEO since May 2015, leading the company to significant growth, including an increase in revenue from $63 million in 2014 to $639 million in 2023. Loeillot, who joined Repligen in October 2023, brings nearly 30 years of industry experience, including leadership roles at Cytiva and GE Healthcare Life Sciences. Current Board Chair Karen A. Dawes will become Lead Independent Director.
Ecolab, in partnership with Repligen , announced the commercial launch of DurA Cycle Affinity Resin, designed for large-scale purification in biologic manufacturing. This product, launched at BIO 2024 in San Diego, targets efficient monoclonal antibody production, reducing costs for biologic drug developers. The launch reflects Ecolab's ongoing commitment to bioprocessing innovations, following two other resins launched in the past eighteen months. The partnership aims to address complex challenges in biologic manufacturing and is bolstered by Ecolab's investment in a new production facility in Landenberg, PA, complementing its UK-based facility.
Repligen (NASDAQ:RGEN) announced its participation in two upcoming June investor conferences.
The company will present at William Blair’s 44th Annual Growth Stock Conference in Chicago from June 4-6, 2024. CEO Tony J. Hunt will give a company overview on June 5 at 12:00 p.m. CT.
Additionally, Repligen will participate in Jefferies’ Global Healthcare Conference in New York from June 5-6, 2024. President and Chief Commercial Officer Olivier Loeillot, and CFO Jason K. Garland, will join an analyst-led discussion on June 6 at 11:30 a.m. ET.
Both presentations will be webcast live and accessible via the company's Investor Relations website.
Repligen (NASDAQ:RGEN) will attend several investor conferences in May, including RBC Capital Markets' Global Healthcare Conference in New York, Craig-Hallum's Institutional Investor Conference in Minneapolis, and Leerink Partners' Healthcare Crossroads Conference in Austin. Jason K. Garland, Chief Financial Officer, will participate in analyst-led discussions and one-on-one meetings with investors at each event. Live webcasts of the RBC and Leerink presentations will be accessible via Repligen's Investor Relations website.
Repligen reported first quarter revenue of $151 million, a 16% increase in new modalities revenue, and a 12% increase in Filtration (non-COVID) revenue year-over-year. The company achieved a nine-month book-to-bill ratio of 1.03. Financial performance in Q1 2024 saw a decline in reported revenue and gross profit compared to Q1 2023, primarily due to COVID-related revenue absence and a decline in Proteins revenue. Adjusted figures showed a decrease in income from operations and net income. Cash, cash equivalents, and short-term investments at the end of Q1 2024 were $780.6 million. Repligen reiterated its financial guidance for full year 2024, expecting orders to pick up in the second half of the year. The company's adjusted financial guidance for FY 2024 remains unchanged, with total reported revenue expected to be in the range of $620M - $650M.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
